BioCentury
ARTICLE | Clinical News

GelTex Cholestagel and Renagel data

February 29, 2000 8:00 AM UTC

GELX said that in a 260-patient placebo-controlled Phase II study of its second-generation Cholestagel non-absorbed bile acid sequestrant, 2 and 3.2 g of the compound decreased LDL cholesterol levels by 12 and 16 percent, respectively. GELX said that its second-generation product required less dosing than first-generation Cholestagel, which is under FDA review. The second-generation compound also had an additive LDL-lowering effect when combined with Merck & Co. Inc.'s Mevacor lovastatin. ...